Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

por Restellini, Sophie, Afif, Waqqas
Publicado 2021

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization

por Rahme, Elham, Nedjar, Hacene, Afif, Waqqas
Publicado 2019

Epidermolysis bullosa acquisita treated with ustekinumab: A case report

por Prosty, Connor, Guirguis, Justina, Chergui, May, Afif, Waqqas, Netchiporouk, Elena
Publicado 2022

Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn’s Disease

por Verdon, Christine, Vande Casteele, Niels, Heron, Valérie, Germain, Pascale, Afif, Waqqas
Publicado 2020

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis

por Wetwittayakhlang, Panu, Golovics, Petra A., Afif, Waqqas, Bessissow, Talat, Lakatos, Peter L.
Publicado 2021

Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn's Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance

por Hahn, Gustavo Drügg, Wetwittayakhlang, Panu, Afif, Waqqas, Bessissow, Talat, Lakatos, Peter L.
Publicado 2022

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring

por Albader, Farah, Golovics, Petra Anna, Gonczi, Lorant, Bessissow, Talat, Afif, Waqqas, Lakatos, Peter Laszlo
Publicado 2021

Medical Summary Template for the Transfer of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care

por Benchimol, Eric I, Afif, Waqqas, Plamondon, Sophie, Newhook, Dennis, Nicholls, Stuart G, Lévesque, Dominique
Publicado 2021

Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study

por Benmassaoud, Amine, Xie, Xuanqian, AlYafi, Motaz, Theoret, Yves, Bitton, Alain, Afif, Waqqas, Bessissow, Talat
Publicado 2016

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease

por Alrajhi, Saad, Germain, Pascale, Martel, Myriam, Lakatos, Peter, Bessissow, Talat, Al-Taweel, Talal, Afif, Waqqas
Publicado 2020

Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians

por Hart, Lara, Chavannes, Mallory, Lakatos, Peter L, Afif, Waqqas, Bitton, Alain, Bressler, Brian, Bessissow, Talat
Publicado 2020

Depression, diabetes and immigration status: a retrospective cohort study using the Canadian Longitudinal Study on Aging

por Farid, Doaa, Li, Patricia, Da Costa, Deborah, Afif, Waqqas, Szabo, Jason, Dasgupta, Kaberi, Rahme, Elham
Publicado 2022

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review

por Al Khoury, Alex, Balram, Bhairavi, Bessissow, Talat, Afif, Waqqas, Gonczi, Lorant, Abreu, Maria, Lakatos, Peter L.
Publicado 2021

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease

por Chao, Che-Yung, Lemieux, Carolyne, Restellini, Sophie, Afif, Waqqas, Bitton, Alain, Lakatos, Peter L., Wild, Gary, Bessissow, Talat
Publicado 2019

Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults

por Lim, Wendy, Afif, Waqqas, Knowles, Sandra, Lim, Gloria, Lin, Yulia, Mothersill, Charmaine, Nistor, Irina, Rehman, Faisal, Song, Christine, Xenodemetropoulos, Ted
Publicado 2019

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease

por Wetwittayakhlang, Panu, Albader, Farah, Golovics, Petra A, Hahn, Gustavo Drügg, Bessissow, Talat, Bitton, Alain, Afif, Waqqas, Wild, Gary, Lakatos, Peter L
Publicado 2021

Ustekinumab Therapeutic Drug Monitoring—Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial

por Afif, Waqqas, Sattin, Bernie, Dajnowiec, Dorota, Khanna, Reena, Seow, Cynthia H., Williamson, Martin, Karra, Kinda, Wang, Yanli, Gao, Long-long, Bressler, Brian
Publicado 2021

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases

por Kablawi, Dana, Aljohani, Faisal, Palumbo, Chiara Saroli, Restellini, Sophie, Bitton, Alain, Wild, Gary, Afif, Waqqas, Lakatos, Peter L, Bessissow, Talat, Sebastiani, Giada
Publicado 2023

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study

por Wetwittayakhlang, Panu, Verdon, Christine, Starr, Michael, Drügg Hahn, Gustavo, Golovics, Petra A., Bessissow, Talat, Afif, Waqqas, Wild, Gary, Bitton, Alain, Lakatos, Peter L.
Publicado 2023

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

por Hahn, Gustavo Drügg, Golovics, Petra Anna, Wetwittayakhlang, Panu, Santa Maria, Dirlene Melo, Britto, Usiara, Wild, Gary Edward, Afif, Waqqas, Bitton, Alain, Bessissow, Talat, Lakatos, Peter Laszlo
Publicado 2022